key: cord-0862429-3sc5u8jk
authors: UK COVID-19 Lateral Flow Oversight Team,; Peto, T.
title: COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing
date: 2021-01-15
journal: nan
DOI: 10.1101/2021.01.13.21249563
sha: 552a573b7dd3a4d58a97fb3a44e18c230fd50fdf
doc_id: 862429
cord_uid: 3sc5u8jk

Background: New lateral flow device (LFD) viral antigen immunoassays have been developed by commercial and research organisations around the world as diagnostic tests for SARS-CoV-2 infection. To support decisions by the UK Government on potential scale-up of mass population testing, we have at their request evaluated the diagnostic performance of a significant number of point-of-care rapid SARS-CoV-2 LFDs. Methods: 132 LFDs were initially reviewed by a Department of Health and Social Care team, part of the UK government, from which 64 were selected for further evaluation. Standardised laboratory evaluations, and for those that met the published criteria, field testing in the Falcon-C19 research study and UK pilots were performed (UK COVID-19 testing centres, hospital, schools, armed forces). Results: 4/64 LFDs so far have desirable performance characteristics from independent laboratory studies and early preliminary field evaluations (Orient Gene, Deepblue and Innova SARS-CoV-2 Antigen Rapid Qualitative Test), of which one underwent extended clinical assessment in field studies (Innova). 8951 Innova LFD tests were performed with a kit failure rate of 5.6% (502/8951, 95% CI: 5.1-6.1), false positive rate of 0.32% (22/6954, 95% CI: 0.20-0.48) and a viral antigen detection/sensitivity (using RNA RT-PCR as a proxy for the presence of antigen) of 78.8% when performed by laboratory scientists (156/198, 95% CI 72.4-84.3). Sensitivity was significantly lower when testing was undertaken by non-experts with limited initial training Interpretation: Several LFDs have promising performance characteristics for mass population testing and can be used to identify infectious positive individuals. The Innova LFD shows good viral antigen detection/sensitivity with excellent specificity, although kit failure rates and the impact of training are potential issues. These results support the expanded evaluation of LFDs, and assessment of greater access to testing on COVID-19 transmission. Funding: Department of Health and Social Care. University of Oxford. Public Health England Porton Down, Manchester University NHS Foundation Trust, National Institute of Health Research.

National governments and international organisations including the World Health Organisation (WHO) and 

Extended Innova LFD evaluation (Phases 2-4)

The limit of detection of the Innova LFD ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.21249563 doi: medRxiv preprint very faint) ( Table 3) .

Evaluation Phase 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted January 15, 2021. ; https://doi.org/10.1101/2021.01.13.21249563 doi: medRxiv preprint SARS-CoV-2 Antigen Rapid Qualitative Test, which has a viral antigen detection (sensitivity) of 78.8% when 251 performed by laboratory scientists and a specificity of 99.7%, using RT-PCR as 'gold standard' for positive and

Commission steps up actions on testing. European Commission -European Commission